PLSE Stock Analysis: Pulse Biosciences | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 2.092m USD | 12M Return: 115.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.81M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pulse Biosciences, Inc. (PLSE) is a U.S.-based bioelectric medicine company headquartered in Miami, Florida, founded in 2014 (formerly Electroblate, Inc., renamed in December 2015). The company develops the nPulse platform, which is built around Nanosecond Pulsed-Field Ablation (nsPFA) technology. Its product line spans dermatology, soft tissue ablation, and cardiac applications, including systems designed for treating atrial fibrillation and skin lesions, along with a console-based software platform to support physician workflows.
The company operates in the medical device sector, specifically within healthcare equipment, where pulsed-field ablation represents an emerging energy modality being investigated as an alternative to traditional thermal ablation methods (such as radiofrequency or cryoablation) for cardiac arrhythmias. Pulse Biosciences is classified as a small-cap stock, indicating a relatively modest market capitalization compared to larger medical device peers.
- FDA approval timeline for cardiac catheter system drives valuation
- Boston Scientific FARAPULSE competition intensifies in pulsed-field ablation market
- Cash burn and dilution risk from ongoing equity capital raises
| Net Income: -74.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.68 > 0.02 and ΔFCF/TA -37.82 > 1.0 |
| NWC/Revenue: 8.17k% < 20% (prev 4.53k%; Δ 3.63k% < -1%) |
| CFO/TA -0.68 > 3% & CFO -55.2m > Net Income -74.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.8m) vs 12m ago 0.99% < -2% |
| Gross Margin: -91.08% > 18% (prev 33.97%; Δ -125.1% > 0.5%) |
| Asset Turnover: 0.70% > 50% (prev 1.87%; Δ -1.17% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 71.1m - Total Current Liabilities 9.80m) / Total Assets 81.6m |
| B: -5.90 (Retained Earnings -481.9m / Total Assets 81.6m) |
| C: -0.70 (EBIT TTM -75.1m / Avg Total Assets 107.5m) |
| D: 4.33 (Book Value of Equity 66.3m / Total Liabilities 15.3m) |
| Altman-Z'' = -14.47 = D |
As of July 28, 2026, the stock is trading at USD 32.79 with a total of 425,405 shares traded. Over the past week, the price has changed by +13.23%, over one month by +12.14%, over three months by +44.77% and over the past year by +115.58%.
Current recommended Stop Loss: 30.50 (which is 7% or 1.1 ATR below the current price).
Pulse Biosciences has no consensus analysts rating.
| Analysts Target Price | 30.7 | -6.5% |
P/S = 2785.8982
P/B = 31.5368
Revenue TTM = 751k USD
EBIT TTM = -75.1m USD
EBITDA TTM = -74.1m USD
Long Term Debt = 5.53m USD (estimated: total debt 7.16m - short term 1.63m)
Short Term Debt = 1.63m USD (from shortTermDebt, last quarter)
Debt = 7.16m USD (from shortLongTermDebtTotal, last quarter) (leases 7.16m already included)
Net Debt = -61.2m USD (calculated: Debt 7.16m - CCE 68.3m)
Enterprise Value = 2.03b USD (2.09b + Debt 7.16m - CCE 68.3m)
Interest Coverage Ratio = unknown (Ebit TTM -75.1m / Interest Expense TTM 0.0)
EV/FCF = -36.60x (Enterprise Value 2.03b / FCF TTM -55.5m)
FCF Yield = -2.73% (FCF TTM -55.5m / Enterprise Value 2.03b)
FCF Margin = -7.39k% (FCF TTM -55.5m / Revenue TTM 751k)
Net Margin = -9.93k% (Net Income TTM -74.6m / Revenue TTM 751k)
Gross Margin = -91.08% ((Revenue TTM 751k - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 7.73% (prev -96.59%)
Tobins Q-Ratio = 24.88 (Enterprise Value 2.03b / Total Assets 81.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 7.16m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -59.4m (EBIT -75.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.26 (Total Current Assets 71.1m / Total Current Liabilities 9.80m)
Debt / Equity = 0.11 (Debt 7.16m / totalStockholderEquity, last quarter 66.3m)
Debt / EBITDA = 0.83 (negative EBITDA) (Net Debt -61.2m / EBITDA -74.1m)
Debt / FCF = 1.10 (negative FCF - burning cash) (Net Debt -61.2m / FCF TTM -55.5m)
Total Stockholder Equity = 86.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.36% (Net Income -74.6m / Total Assets 81.6m)
RoE = -86.67% (Net Income TTM -74.6m / Total Stockholder Equity 86.0m)
RoCE = -82.06% (EBIT -75.1m / Capital Employed (Equity 86.0m + L.T.Debt 5.53m))
RoIC = -80.85% (negative operating profit) (NOPAT -59.4m / Invested Capital 73.4m)
WACC = 9.68% (E(2.09b)/V(2.10b) * Re(9.71%) + D(7.16m)/V(2.10b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.27 | Cagr: 9.69%
[DCF] Fair Price = unknown (Cash Flow -55.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.49 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.00 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=-18.75% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.28 | Chg30d=-18.75% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.07 | Chg30d=-17.58% | Revisions=-25% | GrowthEPS=-41.8% | GrowthRev=+652.4%
EPS next Year (2027-12-31): EPS=-1.09 | Chg30d=-23.86% | Revisions=-25% | GrowthEPS=-1.9% | GrowthRev=+236.7%
[Analyst] Revisions Ratio: -57% (up=0, down=4)